Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells

Haematologica

Volumn 98, Issue 9, 2013, Pages

  Cristóbal, Ion ^a,b   Cirauqui, Cristina ^a   Castello Cros, Remedios ^a   Garcia Orti, Laura ^a   Calasanz, María J ^c   Odero, María D ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

AKT; AML; PP2A; PPP2R5E

Indexed keywords

PHOSPHOPROTEIN PHOSPHATASE 2A;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LETTER; PREVALENCE; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING;

AKT; AML; PP2A; PPP2R5E;

CELL LINE, TUMOR; DOWN-REGULATION; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROTEIN PHOSPHATASE 2;

EID: 84883640913     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.084731     Document Type: Letter

References (15)

1. Perrotti D and Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013;14(6):e229-38.
2. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008;14(4):152-60.
3. Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, et al. Low expression of PP2A regulatory subunit B55alpha is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia. 2011;25(11):1711-7.
4. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent antileukemic effect. Leukemia. 2011;25(4):606-14.
5. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007;117(9):2408-21.
6. Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science. 1999;283(5410):2089-91.
7. Yang J, Wu J, Tan C, Klein PS. PP2A:B56epsilon is required for Wnt/beta-catenin signaling during embryonic development. Development. 2003;130(23):5569-78.
8. Rorick AM, Mei W, Liette NL, Phiel C, El-Hodiri HM, Yang J. PP2A:B56epsilon is required for eye induction and eye field separation. Dev Biol. 2007;302(2):477-93.
9. Jin Z, Wallace L, Harper SQ, Yang J. PP2A:B56{epsilon}, a substrate of caspase-3, regulates p53-dependent and p53-independent apoptosis during development. J Biol Chem. 2010;285(45):34493-502.
10. Yan L, Mieulet V, Burgess D, Findlay GM, Sully K, Procter J, et al. PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR. Mol Cell. 2010;37(5):633-42.
11. Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res. 2010;70(13):5438-47.
12. Sablina AA, Hector M, Colpaert N, Hahn WC. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 2010;70(24):10474-84.
13. Rocher G, Letourneux C, Lenormand P, Porteu F. Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity. J Biol Chem. 2007; 282(8):5468-77.
14. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010; 327(5973):1650-3.
15. Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K, et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol. 2010;12(4):372-9.